Literature DB >> 9457255

Radiation-induced tumors in irradiated stage I testicular seminoma: results of a 25-year follow-up (1968-1993).

M E Stein1, M Leviov, K Drumea, B Moshkovitz, O Nativ, D Milstein, E Sabo, A Kuten.   

Abstract

BACKGROUND AND OBJECTIVES: Testicular seminoma is a very radiosensitive and curable cancer, with survival rates following radiation therapy within the range of 90-98% without apparent severe side effects. However, long-term survival following exposure to moderate-dose radiation therapy can result in radiation-induced tumors.
METHODS: The incidence of radiation-induced tumors was determined in 81 irradiated stage I testicular seminoma patients treated at the Northern Israel Oncology Center (NIOC) from 1968 through 1993.
RESULTS: Three (4%) patients developed second cancers within the high-dose volume. Indeed, those patients received a higher than usual dose to the para-aortic and pelvic regions. One patient, who developed inoperable pancreatic carcinoma, was treated with "hockey stick" field and mediastinal irradiation, plus, as a result of relapses, multiple cisplatin and VP-16 based regimens.
CONCLUSIONS: The elimination of causative factors through lower total doses and field size reduction may reduce the, albeit very low, incidence of radiation-induced cancer in cured testicular seminoma.

Entities:  

Mesh:

Year:  1998        PMID: 9457255     DOI: 10.1002/(sici)1096-9098(199801)67:1<38::aid-jso8>3.0.co;2-n

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  2 in total

1.  "Hockey Stick" may Strike Back: Hepatocellular Carcinoma on Noncirrhotic Liver as a Late Toxicity of Lombo-Aortic Radiotherapy for Seminoma. A Review Triggered by an Unusual Case.

Authors:  Clement Korenbaum; Philippe Barthelemy; Alina Onea; Pierre Salze; Jean-Emmanuel Kurtz
Journal:  J Clin Exp Hepatol       Date:  2015-11-12

2.  Stage I seminoma: treatment outcome at King Hussein Cancer Center in Jordan.

Authors:  Jamal Khader; Ahmed Salem; Yazan Abuodeh; Abdelateif Almousa; Naim Farah; Fadwa Abdelrahman
Journal:  BMC Urol       Date:  2012-04-24       Impact factor: 2.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.